高级搜索

辽宁省三城市社区居民子宫体癌10年生存率分析

Ten-year Survival of Corpus Uteri Cancer Patients in Urban Communities of Three Cities in Liaoning Province

  • 摘要:
    目的 分析辽宁省城市女性子宫体癌患者10年生存率及其影响因素。
    方法 基于辽宁省肿瘤登记报告系统数据库,选取2000—2002年沈阳、鞍山和本溪三市肿瘤发病数据库中子宫体癌患者426例,被动与主动随访相结合,应用寿命表法和Ederer Ⅱ方法分别计算观察生存率(OSR)、期望生存率(ESR)和相对生存率(RSR)。
    结果 最终纳入的218例子宫体癌患者中,Ⅰ~Ⅳ期诊断比例分别为59.2%、11.5%、11.0%和8.7%。10年OSR和RSR分别为59.6%和67.5%。诊断期别越高,10年RSR越低。接受手术治疗患者的10年RSR为71.3%,是非手术治疗(10.8%)的6.6倍。子宫体癌1~10年RSR为88.4%~67.5%,各期别呈现相对生存率Ⅰ~Ⅱ期(95.7%~77.9%) > Ⅲ期(71.4%~44.5%) > Ⅳ期(58.4%~11.0%)的特征。多因素Cox模型分析显示年龄 > 55岁、诊断分期晚、不能手术治疗是影响10年生存率的主要因素。
    结论 早期诊断和手术治疗可显著提高子宫体癌患者的长期生存率。因此,应加强肿瘤的早发现、早治疗,规范筛查方案,加大筛查力度。

     

    Abstract:
    Objective To analyze 10 years survival status of urban female patients with corpus uteri cancer and its influencing factors in Liaoning Province.
    Methods Based on Liaoning cancer register database, 426 patients with corpus uteri cancer in Shenyang, Anshan and Benxi from 2000 to 2002 were randomly selected. They were followed up passively and actively. Life table method and Ederer Ⅱ method were used to calculate the observed survival rate (OSR), the expected survival rate (ESR) and the relative survival rate (RSR).
    Results We finally included 218 corpus uteri patients. The diagnosis proportions of stage Ⅰ-Ⅳ were 59.2%, 11.5%, 11.0% and 8.7%, respectively. Ten-year RSR and OSR were 59.6% and 67.9%. The diagnosis stage was negatively correlated with 10-year RSR. The 10-year RSR of patients treated with surgery was 71.3%, which was 6.6 times that of non-surgical treatment (10.8%). The 1-year RSR to 10-year RSR ranged from 88.4% to 67.5%. The RSR of each stage was Ⅰ-Ⅱ(95.7%-77.9%) > Ⅲ (71.4%-44.5%) > Ⅳ (58.4%-11.0%). Multivariate Cox model analysis showed that age > 55 years old, late diagnosis stage and non-surgical treatment were the main factors affecting the 10-year survival rate.
    Conclusion Early diagnosis and surgical treatment can significantly improve the long-term survival rate of patients. Therefore, we should strengthen the early detection and treatment of corpus uteri cancer, standardize and strengthen the screening program.

     

/

返回文章
返回